Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the transaction, the chief operating officer now directly owns 896,869 shares in the company, valued at $9,551,654.85. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total transaction of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.

Roivant Sciences Trading Down 0.3 %

Shares of Roivant Sciences stock opened at $10.49 on Wednesday. The firm has a fifty day simple moving average of $11.14 and a 200-day simple moving average of $11.60. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06. The stock has a market capitalization of $7.49 billion, a price-to-earnings ratio of -69.93 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, research analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on ROIV. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Roivant Sciences presently has an average rating of “Buy” and a consensus price target of $18.08.

Hedge Funds Weigh In On Roivant Sciences

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its stake in Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after purchasing an additional 1,948 shares during the last quarter. Gladius Capital Management LP acquired a new position in Roivant Sciences during the 3rd quarter valued at $35,000. US Bancorp DE raised its stake in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Roivant Sciences during the 4th quarter valued at $39,000. Finally, GAMMA Investing LLC raised its stake in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.